The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Department of Radiology, John Radcliffe Hospital, Oxford, United Kingdom.
Front Immunol. 2022 Feb 7;13:795463. doi: 10.3389/fimmu.2022.795463. eCollection 2022.
Protection from liver-stage malaria requires high numbers of CD8+ T cells to find and kill -infected cells. A new malaria vaccine strategy, prime-target vaccination, involves sequential viral-vectored vaccination by intramuscular and intravenous routes to target cellular immunity to the liver. Liver tissue-resident memory (TRM) CD8+ T cells have been shown to be necessary and sufficient for protection against rodent malaria by this vaccine regimen. Ultimately, to most faithfully assess immunotherapeutic responses by these local, specialised, hepatic T cells, periodic liver sampling is necessary, however this is not feasible at large scales in human trials. Here, as part of a phase I/II challenge study of prime-target vaccination, we performed deep immune phenotyping, single-cell RNA-sequencing and kinetics of hepatic fine needle aspirates and peripheral blood samples to study liver CD8+ TRM cells and circulating counterparts. We found that while these peripheral 'TRM-like' cells differed to TRM cells in terms of previously described characteristics, they are similar phenotypically and indistinguishable in terms of key T cell residency transcriptional signatures. By exploring the heterogeneity among liver CD8+ TRM cells at single cell resolution we found two main subpopulations that each share expression profiles with blood T cells. Lastly, our work points towards the potential for using TRM-like cells as a correlate of protection by liver-stage malaria vaccines and, in particular, those adopting a prime-target approach. A simple and reproducible correlate of protection would be particularly valuable in trials of liver-stage malaria vaccines as they progress to phase III, large-scale testing in African infants. We provide a blueprint for understanding and monitoring liver TRM cells induced by a prime-target malaria vaccine approach.
预防肝脏阶段疟疾需要大量的 CD8+T 细胞来发现并杀死受感染的细胞。一种新的疟疾疫苗策略——原靶疫苗接种,涉及通过肌肉内和静脉途径的顺序病毒载体疫苗接种,以靶向肝脏的细胞免疫。已经表明,这种疫苗方案中,肝脏组织驻留记忆(TRM)CD8+T 细胞对于预防啮齿动物疟疾是必要和充分的。最终,为了最真实地评估这些局部、专门的肝脏 T 细胞的免疫治疗反应,需要定期进行肝脏取样,但在人体试验中大规模进行这一点是不可行的。在这里,作为原靶疫苗接种的 I/II 期挑战研究的一部分,我们进行了深度免疫表型分析、单细胞 RNA 测序以及肝脏细针抽吸和外周血样本的动力学研究,以研究肝脏 CD8+TRM 细胞和循环对应物。我们发现,虽然这些外周“TRM 样”细胞在以前描述的特征方面与 TRM 细胞不同,但它们在表型上相似,在关键 T 细胞驻留转录特征方面无法区分。通过探索单细胞分辨率下肝脏 CD8+TRM 细胞的异质性,我们发现了两个主要亚群,每个亚群都与血液 T 细胞具有相似的表达谱。最后,我们的工作表明,TRM 样细胞有可能作为肝脏阶段疟疾疫苗保护的相关指标,特别是那些采用原靶方法的疫苗。在这些针对肝脏阶段疟疾疫苗的临床试验进展到 III 期、在非洲婴儿中进行大规模测试时,一个简单且可重复的保护相关性将特别有价值。我们为理解和监测原靶疟疾疫苗接种诱导的肝脏 TRM 细胞提供了一个蓝图。